NEJM:扁平苔癣-病例报道

2018-08-09 xing.T MedSci原创

虽然尚未明确确定扁平苔藓的病因,但它被认为是一种自身免疫性疾病。扁平苔藓与HCV感染有关。在该患者中,已经治疗的HCV感染与后来的皮疹之间的关联尚不清楚。局部或病灶内糖皮质激素可作为主要治疗,紫外线治疗和口服免疫抑制剂用于病变更广泛的病例。

患者为一名69岁的男子,因瘙痒性皮疹2个月而到皮肤科就诊。皮疹首先出现在他的右手腕上,并在2周内扩散到他的手臂、腿部和躯干。既往有慢性丙型肝炎病毒(HCV),他在皮疹发病前3个月完成了为期12周的elbasvir和grazoprevir治疗。



体格检查时,在手臂的前表面(如图A)和手的背面(如图B)以及躯干和腿部可见许多紫色丘疹。几处病灶显示出细小的网点和细纹,称为威克姆纹。病变部位活组织检查显示角化过度,楔形的颗粒状过多,锯齿状的钉突和带状淋巴细胞炎症-这些结果证实了扁平苔藓的诊断

虽然尚未明确确定扁平苔藓的病因,但它被认为是一种自身免疫性疾病。扁平苔藓与HCV感染有关。在该患者中,已经治疗的HCV感染与后来的皮疹之间的关联尚不清楚。局部或病灶内糖皮质激素可作为主要治疗,紫外线治疗和口服免疫抑制剂用于病变更广泛的病例。

该患者接受局部氯倍他索和窄带紫外线B治疗,并在治疗开始后1个月内病变减轻。

原始出处:

Ayan Kusari,et al. Lichen Planus.N Engl J Med 2018; https://www.nejm.org/doi/full/10.1056/NEJMicm1802078

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=338951, encodeId=44b2338951a1, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Aug 16 09:58:42 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337534, encodeId=be1733e53418, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:30:04 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337484, encodeId=f57e33e48443, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 09 08:31:28 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-16 易水河

    学习学习很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=338951, encodeId=44b2338951a1, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Aug 16 09:58:42 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337534, encodeId=be1733e53418, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:30:04 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337484, encodeId=f57e33e48443, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 09 08:31:28 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 哈哈869

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=338951, encodeId=44b2338951a1, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Aug 16 09:58:42 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337534, encodeId=be1733e53418, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:30:04 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337484, encodeId=f57e33e48443, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 09 08:31:28 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 龙胆草

    学习谢谢分享

    0

相关资讯

Aliment Pharmacol Ther:类固醇可有效治疗食管扁平苔癣

食管扁平苔癣是一种特发性炎症性疾病,具有显着的食管狭窄特征。食管扁平苔癣是一个罕见且很难诊断的疾病。目前没有标准化的治疗方法,治疗策略也各不相同。 研究目的是调查类固醇治疗(氟替卡松和布地奈德)对食管扁平苔藓的疗效。 对1995和2016之间在罗切斯特梅奥诊所诊断为食管扁平苔癣的患者进行了回顾性研究。上消化道内镜检查的平均时间为3.2个月(0.7 - 11.7)。吞食类固醇制剂包括氟替